骨肌肉质量和治疗反应之间的关联在患有扩散大B细胞淋巴瘤的患者中
Junice Teresita Sosa-Romero1, Lilia Castillo-Martínez2, Jesús Alejandro Gabutti-Thomas3
1Master in Sciences, Department of Hematology and Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Leukemia & lymphoma
|August 2, 2024
概括
扩散性大B细胞淋巴瘤 (DLBCL) 患者的低骨肌肉质量 (SMM) 不会影响完全缓解,但与整体存活率较差有关. 高血压加剧了这些风险,显著影响了缓解和生存结果.
科学领域:
- 在瘤学瘤学.
- 放射学 放射学是一门学科.
- 临床医学 临床医学
背景情况:
- 低骨肌量 (SMM) 是一种已知的不利预后因素,用于扩散大B细胞淋巴瘤 (DLBCL) 的整体存活率 (OS).
- 在DLBCL中,SMM与治疗反应之间的关联需要进一步调查.
研究的目的:
- 研究分散型大B细胞淋巴瘤 (DLBCL) 患者的低骨肌量 (SMM) 和治疗反应之间的关系.
主要方法:
- 对123名DLBCL患者进行了回顾性队列研究.
- 在化疗前通过计算机断层扫描 (CT) 评估的骨肌肉质量 (SMM).
- 对人口统计数据,治疗方案 (类似R-CHOP),治疗延迟,完全缓解率 (CR) 和整体存活率 (OS) 的分析.
主要成果:
- 与正常SMM患者相比,低SMM患者的平均体重较低,正常BMI比例较高.
- 低SMM与未能实现完全缓解 (CR) 并没有显著关联.
- 在单变量分析中,低SMM是整体存活 (OS) 的风险因素.
- 低SMM和高血压之间的相互作用显著增加了不达到CR和降低OS的风险.
结论:
- 低骨肌量 (SMM) 不是DLBCL患者治疗反应 (CR) 的预测指标.
- 低SMM与DLBCL的总生存率 (OS) 降低有关.
- 低SMM和高血压的组合对DLBCL的治疗结果和生存都有显著的风险因素.
更多相关视频
06:52Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
Published on: September 29, 2014
53.7K
09:18Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
Published on: January 12, 2019
10.3K
相关概念视频
Myasthenia Gravis: Overview and Treatment
1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K
Myasthenia Gravis: Diagnostic Tests
730
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
730
